MIST
Milestone Pharmaceuticals Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $1.41 | $1.46 | +4% |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $1.41 | $1.46 | +4% |
| Two Sigma Investments | Q4 2025(8Q snapshot) | 2Q | $2.00 | $1.46 | -27% |
| Point72 Asset Management | Q1 2026(8Q snapshot) | 1Q | $1.70 | $1.46 | -14% |
| Renaissance Technologies | Q2 2026(8Q snapshot) | 1Q | $1.63 | $1.46 | -10% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| AQR Capital Management | Q4 2025 | Q2 2026 | → $1.50 | -25% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Milestone Pharmaceuticals Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Apr 20, 2026 — the most recent Form 4 on file — not from today.
- Form 40001437782-26-000010Apr 20, 2026
- Form 4/Aamend0001437782-26-000007Feb 5, 2026
- Form 4/Aamend0001910985-26-000006Feb 5, 2026
- Form 4/Aamend0001943112-26-000005Feb 5, 2026
- Form 4/Aamend0001771207-26-000005Feb 5, 2026
- Form 4/Aamend0001787700-26-000005Feb 5, 2026
- Form 40001771207-26-000004Feb 4, 2026
- Form 40001787700-26-000004Feb 4, 2026
- Form 40001943112-26-000004Feb 4, 2026
- Form 40001910985-26-000005Feb 4, 2026
- Form 40001437782-26-000006Feb 4, 2026
- Form 40001910985-26-000003Jan 28, 2026
- Form 40001943112-26-000002Jan 28, 2026
- Form 40001771207-26-000002Jan 28, 2026
- Form 40001787700-26-000002Jan 28, 2026
Fundamentals
XBRL · Milestone Pharmaceuticals Inc.Annual figures sourced directly from Milestone Pharmaceuticals Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Milestone Pharmaceuticals Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- S-3Registration (shelf)May 13, 2026
- 8-KFORM 8-KMay 13, 2026
- 10-QQuarterly reportMay 13, 2026
- DEF 14AFORM DEF 14AApr 30, 2026
- 8-KFORM 8-KMar 20, 2026
- 10-KAnnual reportMar 20, 2026
- 8-KFORM 8-KJan 26, 2026
- 8-KFORM 8-KJan 13, 2026
- 8-KFORM 8-KJan 6, 2026
- 8-KFORM 8-KDec 15, 2025
- 8-KFORM 8-KNov 12, 2025
- 10-QQuarterly reportNov 12, 2025
- 8-KFORM 8-KAug 12, 2025
- 10-QQuarterly reportAug 12, 2025
- 8-KFORM 8-KJul 14, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Renaissance Technologies | Q2 2026 | open | $1.63 | $1.46 | -10% |
| Point72 Asset Management | Q1 2026 | open | $1.70 | $1.46 | -14% |
| Citadel Advisors | Q4 2025 | open | $2.00 | $1.46 | -27% |
| Two Sigma Investments | Q4 2025 | open | $2.00 | $1.46 | -27% |
| AQR Capital Management | Q4 2025 | Q2 2026 | $2.00 | $1.50 | -25% |
| Millennium Management | Q4 2025 | open | $2.00 | $1.46 | -27% |
| Citadel Advisors | Q3 2024 | Q2 2025 | $1.41 | $1.15 | -18% |
| Millennium Management | Q3 2024 | Q3 2025 | $1.41 | $1.68 | +19% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.